GE Healthcare rmp Protein A Sepharose™ Fast Flow Affinity Media

Designed for high-purity separation of monoclonal and polyclonal antibodies

Overview
Brand: GE Healthcare

Manufacturer Part Number: 17513803

200 ML RMP PROTEIN A SEPHAROSE FAST FLOW 200MLstore at 4°C

UNSPSC: 41115700

Code: GX

Additional Details:
Additional Details: Weight: 0.36200kg



Product Code. 10358374

Quantity Price
1 £ 4010.77 / 200mL
Estimated Shipment
15-12-2016
Add to basket

If this item is out of stock, delivery will be in 3-4 working days providing the item is in stock at the supplier.
Please enquire with customer services on 01509 555500 for stock availability.

 

Description and Specification

Specification

Quantity 200mL
Stability Stable in aqueous Buffers commonly used in Protein A Chromatography
Storage Requirements 2 to 8°C
Binding Capacity >Min. 22mg Human IgG/mL
Product Type rmp Protein A Sepharose fast flow media
For Use With (Application) For high-purity separation of monoclonal and polyclonal antibodies
Flow Rate 150 to 250cm/Hour
Particle Size 60 to 165μm
Height (Metric) Bed 25cm
Max. Pressure 100kPa
Matrix 4% Cross-Linked Agarose
pH Range 3 to 10
Storage Buffer 20% Ethanol
Ligand Type Recombinant Protein A (E. coli)

  • Non-mammalian-based media composed of recombinant Protein A coupled with Sepharose 4 Fast Flow base matrix by reductive amination
  • Coupling chemistry that minimizes leakage of protein A ligand
  • Multi-point attachment of rProtein A by chemically-stable amide bonds
  • High capacity and good pressure/flow characteristics provide for high throughput

  • Matrix: 4% cross-linked agarose
  • Average particle size: 90μm (d50V)
  • Ligand: recombinant protein A (E. coli)
  • pH Stability working range: 3 to 10
  • pH Stability cleaning-in-place: 2 to 11
  • Binding capacity/mL chromatography medium: >35mg human IgG/mL
  • Pressure/Flow specification: base matrix 150 to 250cm/hr., 100kPa, XK 50/60 column

For therapeutic applications requiring extremely pure eluate fractions of antibodies with non-exposure of antibodies to human or animal derivatives during purification process.